GeoVax Labs (GOVX) Projected to Post Earnings on Tuesday

GeoVax Labs (NASDAQ:GOVX) is anticipated to release its Q1 2025 earnings data before the market opens on Tuesday, May 13th. Analysts expect GeoVax Labs to post earnings of ($0.51) per share and revenue of $1.75 million for the quarter.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.14. The firm had revenue of $1.64 million for the quarter, compared to the consensus estimate of $0.75 million. On average, analysts expect GeoVax Labs to post $-4 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

GeoVax Labs Price Performance

Shares of NASDAQ:GOVX opened at $0.93 on Friday. GeoVax Labs has a 1 year low of $0.73 and a 1 year high of $11.18. The stock has a market capitalization of $14.09 million, a price-to-earnings ratio of -0.25 and a beta of 3.47. The company’s 50 day simple moving average is $1.16 and its 200 day simple moving average is $1.82.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of GeoVax Labs in a report on Wednesday, April 16th. Alliance Global Partners decreased their target price on GeoVax Labs from $15.00 to $8.50 and set a “buy” rating on the stock in a research report on Tuesday, April 15th. Finally, D. Boral Capital dropped their target price on shares of GeoVax Labs from $14.00 to $9.00 and set a “buy” rating for the company in a report on Friday, May 2nd. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $11.10.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.